Az atípusos antipszichotikumok hatékonysága és a dopamin D3-receptor polimorfizmusának kapcsolata schizophreniában.

Translated title of the contribution: Correlation between the effectiveness of atypical antipsychotics and dopamine D3 receptor polymorphism in schizophrenia

G. Szekeres, A. Juhász, S. Kéri, A. Rimanóczy, István Szendi, Zoltán Szabó, Z. Janka

Research output: Contribution to journalArticle

Abstract

OBJECT: Numerous relevant variants of dopamine receptors have been identified in schizophrenia. The Ser9Gly gene polymorphism of dopamine D3 receptor is known as a susceptibility factor for the disease. In addition, it has a role in the modification of therapeutic effect of antipsychotics. In this naturalistic study the authors investigated the relationship between this polymorphism and the therapeutic response to atypical antipsychotics. METHOD: 75 patients with schizophrenia according to DSM-IV and 45 healthy controls were recruited. The patients were divided to responder and nonresponder subgroups, cut-off: > 20 point improvement in Global Assessment of Functioning. By polymerase chain reaction the genotype of dopamine D3 receptor of every participant was determined. RESULTS: The Ser9Ser genotype of dopamine D3 receptor was more frequent in the nonresponder subgroup (64%, p = 0.0018). The Ser9 allele was overrepresented among nonresponder patients (82%, p = 0.0172). CONCLUSION: Based on our results, the worse therapeutic response to atypical antipsychotics is associated with Ser9 variant of dopamine D3 receptor.

Original languageHungarian
Pages (from-to)377-381
Number of pages5
JournalIdeggyógyászati szemle
Volume55
Issue number11-12
Publication statusPublished - Nov 20 2002

Fingerprint

Dopamine D3 Receptors
Antipsychotic Agents
Schizophrenia
Genotype
Disease Susceptibility
Dopamine Receptors
Therapeutic Uses
Diagnostic and Statistical Manual of Mental Disorders
Alleles
Polymerase Chain Reaction
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az atípusos antipszichotikumok hatékonysága és a dopamin D3-receptor polimorfizmusának kapcsolata schizophreniában. / Szekeres, G.; Juhász, A.; Kéri, S.; Rimanóczy, A.; Szendi, István; Szabó, Zoltán; Janka, Z.

In: Ideggyógyászati szemle, Vol. 55, No. 11-12, 20.11.2002, p. 377-381.

Research output: Contribution to journalArticle

@article{007293128f444a1f93ab73403811a287,
title = "Az at{\'i}pusos antipszichotikumok hat{\'e}konys{\'a}ga {\'e}s a dopamin D3-receptor polimorfizmus{\'a}nak kapcsolata schizophreni{\'a}ban.",
abstract = "OBJECT: Numerous relevant variants of dopamine receptors have been identified in schizophrenia. The Ser9Gly gene polymorphism of dopamine D3 receptor is known as a susceptibility factor for the disease. In addition, it has a role in the modification of therapeutic effect of antipsychotics. In this naturalistic study the authors investigated the relationship between this polymorphism and the therapeutic response to atypical antipsychotics. METHOD: 75 patients with schizophrenia according to DSM-IV and 45 healthy controls were recruited. The patients were divided to responder and nonresponder subgroups, cut-off: > 20 point improvement in Global Assessment of Functioning. By polymerase chain reaction the genotype of dopamine D3 receptor of every participant was determined. RESULTS: The Ser9Ser genotype of dopamine D3 receptor was more frequent in the nonresponder subgroup (64{\%}, p = 0.0018). The Ser9 allele was overrepresented among nonresponder patients (82{\%}, p = 0.0172). CONCLUSION: Based on our results, the worse therapeutic response to atypical antipsychotics is associated with Ser9 variant of dopamine D3 receptor.",
author = "G. Szekeres and A. Juh{\'a}sz and S. K{\'e}ri and A. Riman{\'o}czy and Istv{\'a}n Szendi and Zolt{\'a}n Szab{\'o} and Z. Janka",
year = "2002",
month = "11",
day = "20",
language = "Hungarian",
volume = "55",
pages = "377--381",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "11-12",

}

TY - JOUR

T1 - Az atípusos antipszichotikumok hatékonysága és a dopamin D3-receptor polimorfizmusának kapcsolata schizophreniában.

AU - Szekeres, G.

AU - Juhász, A.

AU - Kéri, S.

AU - Rimanóczy, A.

AU - Szendi, István

AU - Szabó, Zoltán

AU - Janka, Z.

PY - 2002/11/20

Y1 - 2002/11/20

N2 - OBJECT: Numerous relevant variants of dopamine receptors have been identified in schizophrenia. The Ser9Gly gene polymorphism of dopamine D3 receptor is known as a susceptibility factor for the disease. In addition, it has a role in the modification of therapeutic effect of antipsychotics. In this naturalistic study the authors investigated the relationship between this polymorphism and the therapeutic response to atypical antipsychotics. METHOD: 75 patients with schizophrenia according to DSM-IV and 45 healthy controls were recruited. The patients were divided to responder and nonresponder subgroups, cut-off: > 20 point improvement in Global Assessment of Functioning. By polymerase chain reaction the genotype of dopamine D3 receptor of every participant was determined. RESULTS: The Ser9Ser genotype of dopamine D3 receptor was more frequent in the nonresponder subgroup (64%, p = 0.0018). The Ser9 allele was overrepresented among nonresponder patients (82%, p = 0.0172). CONCLUSION: Based on our results, the worse therapeutic response to atypical antipsychotics is associated with Ser9 variant of dopamine D3 receptor.

AB - OBJECT: Numerous relevant variants of dopamine receptors have been identified in schizophrenia. The Ser9Gly gene polymorphism of dopamine D3 receptor is known as a susceptibility factor for the disease. In addition, it has a role in the modification of therapeutic effect of antipsychotics. In this naturalistic study the authors investigated the relationship between this polymorphism and the therapeutic response to atypical antipsychotics. METHOD: 75 patients with schizophrenia according to DSM-IV and 45 healthy controls were recruited. The patients were divided to responder and nonresponder subgroups, cut-off: > 20 point improvement in Global Assessment of Functioning. By polymerase chain reaction the genotype of dopamine D3 receptor of every participant was determined. RESULTS: The Ser9Ser genotype of dopamine D3 receptor was more frequent in the nonresponder subgroup (64%, p = 0.0018). The Ser9 allele was overrepresented among nonresponder patients (82%, p = 0.0172). CONCLUSION: Based on our results, the worse therapeutic response to atypical antipsychotics is associated with Ser9 variant of dopamine D3 receptor.

UR - http://www.scopus.com/inward/record.url?scp=0037146527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037146527&partnerID=8YFLogxK

M3 - Article

C2 - 12632798

AN - SCOPUS:0037146527

VL - 55

SP - 377

EP - 381

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 11-12

ER -